---

Highlights of Deals in August 2024

 

1.     Dr Reddy's invests INR 734 crore(US$87.42 Million) in JV with Nestle India (Nutrition).

2.     Medi Assist to acquire Paramount Health at enterprise value of INR 312 crore (US$37.3 Million).

3.     Zynext Ventures Invests in neuro42, a company developing Portable MRI Systems for Neuroimaging and interventions.

4.     Alkem MedTech inks agreement with Exactech to manufacture, market large joint replacement implants in India.

5.     Biocon Biologics Inks Pact with JJ and Janssen Arms to Market 'Bmab' in Europe and Japan.

6.     Skanray collaborates with Tata Elxsi to develop advanced surgical imaging technology.

7.     Japan's Otsuka Pharma to pay up to US$1.1 Billion to acquire Jnana Therapeutics.

8.     Valneva and LimmaTech agree on license deal for Shigella vaccine.

9.     3PBioVian partners with Rokote for COVID-19 vaccine trials.

10. Eli Lilly doubles down on Oblique partnership for antibody generation.

11.  Flagship-founded Quotient enters collaboration with Pfizer.

12.  Gothenburg and AstraZeneca collaborate to strengthen the life science sector.

13.  Rokote Laboratories signs an agreement with 3PBIOVIAN.

14.  Getinge to acquire Paragonix Technologies.

 

Aagami Updates:

1.     Success Story: Venture Capital Arm of a large global pharma group invests in yet another Aagami MedTech client from California.

2.     Aagami received extension from a US based client with clinical drug to target MDS and several other indications.

3.     Meet us during 

a.     BIO Japan | October 9-11, 2024 | Pacifico Yokohama

b.     And in Republic of Korea | October 14-16, 2024 | Seoul

c.     Also in  BIO EUROPE | November 4–6, 2024 | Stockholm, Sweden  

INFOCUS: Select opportunities available:

For Partnering/Licensing/ Co-development:

1.     Seeking Licensing/Partnering: Phase 2 Drug poised to revolutionize antiviral treatment; could be a single drug to treat all the "tripledemic" viruses.

2.     Licensing: Several Biosimilars available for Partnering in multiple regions like Japan

a.     Denosumab (Prolia® & Xgeva®)

b.     Romiplostim (Nplate®) [ For immune thrombocytopenia (ITP) ]

c.     Teriparatide (Forteo®/Forsteo®) [ For Osteoporosis ]

d.     Liraglutide (Victoza®) [ For Diabetes ]

e.     Tocilizumab (Actemra®) [ For Rheumatoid arthritis (RA), Giant Cell Arteritis (GCA), Active Polyarticular Juvenile Idiopathic Arthritis (PJIA), Active Systemic Juvenile Idiopathic Arthritis (SJIA), Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) and patients with coronavirus disease 2019 (COVID-19) receiving systemic corticosteroids and requiring supplemental oxygen or mechanical ventilation. ]

3.     Seeking Acquisition /JV – Smart Drug preventing Myelodysplastic Syndromes (MDS) from advancing to full-scale myelogenous Leukemia (Second Human Trial ongoing in AU).

4. Seeking Partnering: Nose to brain Delivery using known small molecules targeting orphan diseases such as FrontoTemporal Dementia (FTD) [Orphan Drug Designation Granted by US FDA], Alzheimer’s disease, Parkinson's disease, and Dementia with Lewy Bodies. Two new assets added – For 1) Depression and ALS 2) Anti-Obesity.

For Acquisition:

1.    Sale of equity owned by an Investor who passed away (in a genetic engineering and therapeutics Co. from New York)

2.    Available at a very reasonable price Mountain View Pharma (MVP) including its PharmaPEG® technology, product candidates, data package of ~20 drug candidates, IP etc.- for Next-generation biologics and substantial returns.

3.     IP/Asset sale: A small molecule NSAID combination for Migraine and other indications using 505(b)(2).

4.     Asset sale - US client’s Smart Drug preventing Myelodysplastic Syndromes (MDS) from advancing to full-scale myelogenous Leukemia (Second Human Trial of 30 patients ongoing in AU).

Seeking Investment:

1. Seeking Investment: Human-derived, chimeric therapeutic peptide. Phase 2b stage in Atopic Dermatitis. Novel well understood MoA. Strong patent position supportive of various multi-billion- dollar markets and multiple applications.
2. Seeking US$3 million: Nose to brain Delivery using known small molecules targeting orphan diseases such as FrontoTemporal Dementia (FTD) [Orphan Drug Designation Granted by US FDA], Alzheimer’s disease, Parkinson's disease, and Dementia with Lewy Bodies. Two new assets added – 1. For Depression and ALS 2. Anti-Obesity.
3. Seeking US$2 million: Integrated Autoimmune company - Engineering Therapeutics to Block Pathogenic Autoantibodies

Hope you found the content useful. We welcome your feedback and queries.